A M Lucassen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8772062/publications.pdf

Version: 2024-02-01

50566 45040 9,982 190 48 94 citations h-index g-index papers 195 195 195 13158 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Beyond regulatory approaches to ethics: making space for ethical preparedness in healthcare research. Journal of Medical Ethics, 2023, 49, 352-356.	1.0	9
2	Re-imagining †the patient': Linked lives and lessons from genomic medicine. Social Science and Medicine, 2022, 297, 114806.	1.8	10
3	Public Trust and Trustworthiness in Biobanking: The Need for More Reflexivity. Biopreservation and Biobanking, 2022, , .	0.5	5
4	Sustainable biobanks: a case study for a green global bioethics. Global Bioethics, 2022, 33, 50-64.	0.5	10
5	In the family: access to, and communication of, familial information in clinical practice. Human Genetics, 2022, 141, 1053-1058.	1.8	2
6	Ethical Considerations in Research with Genomic Data. New Bioethics, 2022, , 1-15.	0.5	3
7	Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). Genetics in Medicine, 2022, 24, 1867-1877.	1.1	12
8	What is the meaning of a â€~genomic result' in the context of pregnancy?. European Journal of Human Genetics, 2021, 29, 225-230.	1.4	5
9	Mitochondrial DNA variants in genomic data: diagnostic uplifts and predictive implications. Nature Reviews Genetics, 2021, 22, 547-548.	7.7	3
10	Couple-based expanded carrier screening provided by general practitioners to couples in the Dutch general population: psychological outcomes and reproductive intentions. Genetics in Medicine, 2021, 23, 1761-1768.	1.1	10
11	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	5.1	58
12	Care of men with cancer-predisposing BRCA variants. BMJ, The, 2021, 375, n2376.	3.0	1
13	Using a biomarker acutely to identify babies at risk of serious adverse effects from antibiotics: where is the †Terrible Moral and Medical Dilemma'?. Journal of Medical Ethics, 2021, 47, 117-118.	1.0	0
14	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
15	Genome sequencing in healthcare: understanding the UK general public's views and implications for clinical practice. European Journal of Human Genetics, 2020, 28, 155-164.	1.4	15
16	GP-provided couple-based expanded preconception carrier screening in the Dutch general population: who accepts the test-offer and why?. European Journal of Human Genetics, 2020, 28, 182-192.	1.4	15
17	International perspectives on the implementation of reproductive carrier screening. Prenatal Diagnosis, 2020, 40, 301-310.	1.1	60
18	Using biomarkers in acute medicine to prevent hearing loss: should this require specific consent?. Journal of Medical Ethics, 2020, 46, 536-537.	1.0	5

#	Article	IF	CITATIONS
19	From Beyond the Grave: Use of Medical Information from the Deceased to Guide Care of Living Relatives. Current Genetic Medicine Reports, 2020, 8, 147-153.	1.9	3
20	Cognitive and affective outcomes of genetic counselling in the Netherlands at group and individual level: a personalized approach seems necessary. European Journal of Human Genetics, 2020, 28, 1187-1195.	1.4	8
21	Old consent and new developments: health professionals should ask and not presume. Journal of Medical Ethics, 2020, 46, 412-413.	1.0	1
22	Exploring broad consent in the context of the 100,000 Genomes Project: a mixed methods study. European Journal of Human Genetics, 2020, 28, 732-741.	1.4	24
23	The Need for Machine-Processable Agreements in Health Data Management. Algorithms, 2020, 13, 87.	1.2	3
24	The Secret Life of Immortal Data. , 2020, , .		0
25	When genomic medicine reveals misattributed genetic relationshipsâ€"the debate about disclosure revisited. Genetics in Medicine, 2019, 21, 97-101.	1.1	7
26	Consent and Autonomy in the Genomics Era. Current Genetic Medicine Reports, 2019, 7, 85-91.	1.9	30
27	European recommendations integrating genetic testing into multidisciplinary management of sudden cardiac death. European Journal of Human Genetics, 2019, 27, 1763-1773.	1.4	78
28	Genomic testing in healthcare: a hybrid space where clinical practice and research need to co-exist. Expert Review of Molecular Diagnostics, 2019, 19, 963-967.	1.5	6
29	Direct-to-consumer genetic testing. BMJ: British Medical Journal, 2019, 367, 15688.	2.4	64
30	A validated PROM in genetic counselling: the psychometric properties of the Dutch version of the Genetic Counselling Outcome Scale. European Journal of Human Genetics, 2019, 27, 681-690.	1.4	12
31	Unpacking the Concept of a Genomic Result. American Journal of Bioethics, 2019, 19, 70-71.	0.5	6
32	Familial genetic risks: how can we better navigate patient confidentiality and appropriate risk disclosure to relatives?. Journal of Medical Ethics, 2019, 45, 504-507.	1.0	34
33	Recent developments in genetic/genomic medicine. Clinical Science, 2019, 133, 697-708.	1.8	80
34	The moral argument for heritable genome editing requires an inappropriately deterministic view of genetics. Journal of Medical Ethics, 2019, 45, 526-527.	1.0	5
35	Feasibility of couple-based expanded carrier screening offered by general practitioners. European Journal of Human Genetics, 2019, 27, 691-700.	1.4	48
36	Expanded carrier screening for autosomal recessive conditions in health care: Arguments for a coupleâ€based approach and examination of couples' views. Prenatal Diagnosis, 2019, 39, 369-378.	1.1	20

#	Article	IF	CITATIONS
37	Is it acceptable to contact an anonymous egg donor to facilitate diagnostic genetic testing for the donor-conceived child?. Journal of Medical Ethics, 2019, 45, 357-360.	1.0	10
38	Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists. BMC Medical Genomics, 2019, 12, 170.	0.7	33
39	Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 2019, 27, 169-182.	1.4	65
40	Fostering trust in healthcare: Participants' experiences, views, and concerns about the 100,000 genomes project. European Journal of Medical Genetics, 2019, 62, 335-341.	0.7	20
41	Direct-to-consumer genetic testing with third party interpretation: beware of spurious results. Emerging Topics in Life Sciences, 2019, 3, 669-674.	1.1	9
42	Genomic variant sharing: a position statement. Wellcome Open Research, 2019, 4, 22.	0.9	31
43	Potential for diagnosis of infectious disease from the 100,000 Genomes Project Metagenomic Dataset: Recommendations for reporting results. Wellcome Open Research, 2019, 4, 155.	0.9	9
44	Recontacting or not recontacting? A survey of current practices in clinical genetics centres in European Journal of Human Genetics, 2018, 26, 946-954.	1.4	33
45	Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100 000 genomes project. Journal of Medical Ethics, 2018, 44, 397-403.	1.0	29
46	The Road to Clinical Fantasy: A UK Perspective. American Journal of Bioethics, 2018, 18, 26-27.	0.5	2
47	How do clinical genetics consent forms address the familial approach to confidentiality and incidental findings? A mixed-methods study. Familial Cancer, 2018, 17, 155-166.	0.9	10
48	Limitations and Pitfalls of Using Family Letters to Communicate Genetic Risk: a Qualitative Study with Patients and Healthcare Professionals. Journal of Genetic Counseling, 2018, 27, 689-701.	0.9	51
49	Disclosure of genetic information to relatives: balancing confidentiality and relatives' interests. Journal of Medical Genetics, 2018, 55, 285-286.	1.5	9
50	Dimensions of responsibility in medical genetics: exploring the complexity of the "duty to recontact― New Genetics and Society, 2018, 37, 187-206.	0.7	4
51	In Defense of Best Interests: When Parents and Clinicians Disagree. American Journal of Bioethics, 2018, 18, 67-69.	0.5	5
52	Alerting relatives about heritable risks: the limits of confidentiality. BMJ: British Medical Journal, 2018, 361, k1409.	2.4	19
53	Using a genetic test result in the care of family members: how does the duty of confidentiality apply?. European Journal of Human Genetics, 2018, 26, 955-959.	1.4	24
54	Predictive Genetic Testing of Children for Adultâ€Onset Conditions: Negotiating Requests with Parents. Journal of Genetic Counseling, 2017, 26, 244-250.	0.9	16

#	Article	IF	CITATIONS
55	Recontacting in clinical genetics and genomic medicine? We need to talk about it. European Journal of Human Genetics, 2017, 25, 520-521.	1.4	16
56	Expanded carrier screening: what determines intended participation and can this be influenced by message framing and narrative information?. European Journal of Human Genetics, 2017, 25, 793-800.	1.4	17
57	A 'joint venture' model of recontacting in clinical genomics: challenges for responsible implementation. European Journal of Medical Genetics, 2017, 60, 403-409.	0.7	36
58	Recontacting in clinical practice: an investigation of the views of healthcare professionals and clinical scientists in the United Kingdom. European Journal of Human Genetics, 2017, 25, 275-279.	1.4	35
59	Approaching confidentiality at a familial level in genomic medicine: a focus group study with healthcare professionals. BMJ Open, 2017, 7, e012443.	0.8	36
60	Recontacting in clinical practice: the views and expectations of patients in the United Kingdom. European Journal of Human Genetics, 2017, 25, 1106-1112.	1.4	23
61	Healthcare professionals' and patients' perspectives on consent to clinical genetic testing: moving towards a more relational approach. BMC Medical Ethics, 2017, 18, 47.	1.0	49
62	Ethical issues in genetic medicine. InnovAiT, 2017, 10, 481-488.	0.0	3
63	Genomic Analysis in Clinical Practice. , 2016, , 191-199.		0
64	What results to disclose, when, and who decides? Healthcare professionals' views on prenatal chromosomal microarray analysis. Prenatal Diagnosis, 2016, 36, 252-259.	1,1	28
65	†Is this knowledge mine and nobody else's? I don't feel that.' Patient views about consent, confidentiality and information-sharing in genetic medicine: TableÂ1. Journal of Medical Ethics, 2016, 42, 174-179.	1.0	58
66	Recontact in clinical practice: a survey of clinical genetics services in the United Kingdom. Genetics in Medicine, 2016, 18, 876-881.	1.1	40
67	Population-based preconception carrier screening: how potential users from the general population view a test for 50 serious diseases. European Journal of Human Genetics, 2016, 24, 1417-1423.	1.4	70
68	Responsible implementation of expanded carrier screening. European Journal of Human Genetics, 2016, 24, e1-e12.	1.4	240
69	Relative Risk and Relatives' Risks in Genomic Medicine. American Journal of Bioethics, 2016, 16, 25-27.	0.5	9
70	Telemedicine uptake among Genetics Professionals in Europe: room for expansion. European Journal of Human Genetics, 2016, 24, 157-163.	1.4	33
71	Health-care professionals' responsibility to patients' relatives in genetic medicine: a systematic review and synthesis of empirical research. Genetics in Medicine, 2016, 18, 290-301.	1.1	76
72	Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature. Genetics in Medicine, 2015, 17, 668-678.	1,1	77

#	Article	IF	Citations
73	Rescue Obligations and Collective Approaches: Complexities in Genomics. American Journal of Bioethics, 2015, 15, 23-25.	0.5	3
74	Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Summary and recommendations. European Journal of Human Genetics, 2015, , .	1.4	13
75	Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. European Journal of Human Genetics, 2015, 23, 1438-1450.	1.4	260
76	Genetic testing of children for adult-onset conditions: opinions of the British adult population and implications for clinical practice. European Journal of Human Genetics, 2015, 23, 1281-1285.	1.4	21
77	I Had Genetic Testing for Alzheimer's Disease Without My Consent. Narrative Inquiry in Bioethics, 2015, 5, 214-216.	0.0	3
78	The Challenges of Genome Analysis in the Health Care Setting. Genes, 2014, 5, 576-585.	1.0	21
79	Genetic Testing of Children: The Need for a Family Perspective. American Journal of Bioethics, 2014, 14, 26-28.	0.5	7
80	Defining and managing incidental findings in genetic and genomic practice. Journal of Medical Genetics, 2014, 51, 715-723.	1.5	58
81	A more fitting term in the incidental findings debate: one term does not fit all situations. European Journal of Human Genetics, 2014, 22, 957-957.	1.4	9
82	Prenatal diagnosis of chromosomal imbalances. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, F338-F341.	1.4	4
83	Rare Variants in NR2F2 Cause Congenital Heart Defects in Humans. American Journal of Human Genetics, 2014, 94, 574-585.	2.6	146
84	Genetic medicine and incidental findings: it is more complicated than deciding whether to disclose or not. Genetics in Medicine, 2013, 15, 896-899.	1.1	31
85	Next Generation Diagnostics in Inherited Arrhythmia Syndromes. Journal of Cardiovascular Translational Research, 2013, 6, 94-103.	1.1	31
86	Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature Genetics, 2013, 45, 136-144.	9.4	851
87	Developing a policy for paediatric biobanks: principles for good practice. European Journal of Human Genetics, 2013, 21, 2-7.	1.4	63
88	Consent and confidentiality in clinical genetic practice: guidance on genetic testing and sharing genetic information. Clinical Medicine, 2012, 12, 5-6.	0.8	21
89	Genomic medicine: challenges and opportunities for physicians. Clinical Medicine, 2012, 12, 416-419.	0.8	19
90	Testing children for adult onset conditions: the importance of contextual clinical judgement. Journal of Medical Ethics, 2012, 38, 531-532.	1.0	9

#	Article	IF	CITATIONS
91	A primary care specialist genetics service: a cluster-randomised factorial trial. British Journal of General Practice, 2012, 62, e191-e197.	0.7	12
92	Ethical implications of new genetic technologies. Developmental Medicine and Child Neurology, 2012, 54, 196-196.	1.1	4
93	The impact of cancer pathology confirmation on clinical management of a family history of cancer. Familial Cancer, 2011, 10, 373-380.	0.9	7
94	No evidence of RET germline mutations in familial pituitary adenoma. Journal of Molecular Endocrinology, 2011, 46, 1-8.	1.1	35
95	The shifting sands of patient autonomy and public interest considerations in health care. Clinical Ethics, 2011, 6, 203-206.	0.5	2
96	Mainstreaming genetics: the potential for miscommunication. Clinical Ethics, 2011, 6, 159-161.	0.5	0
97	Clinical Ethics Committee Case 14: How should we transfer a euthanasia request between general practice and a hospital setting?. Clinical Ethics, 2011, 6, 58-63.	0.5	1
98	What Facilitates or Impedes Family Communication Following Genetic Testing for Cancer Risk? A Systematic Review and Metaâ€synthesis of Primary Qualitative Research. Journal of Genetic Counseling, 2010, 19, 330-342.	0.9	144
99	Predictive genetic testing in a young child: a case report. Familial Cancer, 2010, 9, 61-64.	0.9	2
100	Predictive genetic testing in children: where are we now? An overview and a UK perspective. Familial Cancer, 2010, 9, 3-7.	0.9	8
101	Introduction. Familial Cancer, 2010, 9, 1-1.	0.9	1
102	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 2010, 42, 973-977.	9.4	335
103	Legal implications of tissue. Annals of the Royal College of Surgeons of England, 2010, 92, 189-192.	0.3	2
104	Family history and adoption in the UK: conflicts of interest in medical disclosure. Archives of Disease in Childhood, 2010, 95, 7-11.	1.0	8
105	An investigation of patients' motivations for their participation in genetics-related research. Journal of Medical Ethics, 2010, 36, 37-45.	1.0	97
106	'Ethnicity testing' before adoption: a help or hindrance?. Archives of Disease in Childhood, 2010, 95, 404-405.	1.0	2
107	Lay and Professional Understandings of Research and Clinical Activities in Cancer Genetics and Their Implications for Informed Consent. American Journal of Bioethics Primary Research, 2010, 1, 25-34.	1.5	5
108	Confidentiality and sharing genetic information with relatives. Lancet, The, 2010, 375, 1507-1509.	6.3	28

#	Article	IF	Citations
109	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut, 2010, 59, 666-689.	6.1	1,000
110	Ethicolegal Aspects of Genetics in Surgical Practice. Annals of the Royal College of Surgeons of England, 2009, 91, 451-455.	0.3	0
111	â€~Over-the-counter' genetic testing: what does it really mean for primary care?. British Journal of General Practice, 2009, 59, 283-287.	0.7	41
112	Healthcare professionals' and researchers' understanding of cancer genetics activities: a qualitative interview study. Journal of Medical Ethics, 2009, 35, 113-119.	1.0	24
113	Distinguishing research from clinical care in cancer genetics: Theoretical justifications and practical strategies. Social Science and Medicine, 2009, 68, 2010-2017.	1.8	46
114	Missed threads. EMBO Reports, 2009, 10, 810-816.	2.0	107
115	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	1.5	80
116	Two children with subtelomeric 11q deletions: a description and interpretation of their clinical presentations and molecular genetic findings. Clinical Dysmorphology, 2009, 18, 98-102.	0.1	2
117	Deciphering the genetics of hereditary non-syndromic colorectal cancer. European Journal of Human Genetics, 2008, 16, 1477-1486.	1.4	31
118	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630.	9.4	514
119	Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Human Molecular Genetics, 2008, 17, 3720-3727.	1.4	61
120	Unregulated smooth-muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5513-5518.	3.3	77
121	Ethical Issues in Genetic Medicine. InnovAiT, 2008, 1, 589-595.	0.0	0
122	Recall of participation in research projects in cancer genetics: some implications for research ethics. Clinical Ethics, 2008, 3, 180-184.	0.5	11
123	Ethics and research governance: the views of researchers, health-care professionals and other stakeholders. Clinical Ethics, 2008, 3, 85-90.	0.5	12
124	Disclosure of genetic information within families: a case report. Clinical Ethics, 2008, 3, 7-10.	0.5	0
125	Large Genomic Deletions in <i>AlP</i> i>in Pituitary Adenoma Predisposition. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4146-4151.	1.8	74
126	Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3321-3325.	1.8	262

#	Article	IF	CITATIONS
127	Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. Journal of Medical Genetics, 2007, 44, 579-585.	1.5	172
128	Should families own genetic information? Yes. BMJ: British Medical Journal, 2007, 335, 22-22.	2.4	17
129	Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. International Journal of Cancer, 2007, 121, 1017-1020.	2.3	86
130	Applying a cognitive behavioral model of health anxiety in a cancer genetics service Health Psychology, 2006, 25, 171-180.	1.3	25
131	Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociology of Health and Illness, 2006, 28, 060926022052001-???.	1.1	86
132	Feasibility and acceptability of providing nurse counsellor genetics clinics in primary care. Journal of Advanced Nursing, 2006, 53, 591-604.	1.5	25
133	Implications of data protection legislation for family history. BMJ: British Medical Journal, 2006, 332, 299-301.	2.4	19
134	Genetic testing without consent: the implications of the new Human Tissue Act 2004. Journal of Medical Ethics, 2006, 32, 690-692.	1.0	10
135	Evidence for a colorectal cancer susceptibility locus on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 2903-2910.	1.4	52
136	Evidence for a colorectal cancer susceptibility locus on chromosome 3q21–q24 from a high-density SNP genome-wide linkage scan. Human Molecular Genetics, 2006, 15, 3592-3592.	1.4	0
137	The UK Genethics Club: clinical ethics support for genetic services. Clinical Ethics, 2006, 1, 219-223.	0.5	5
138	Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. Clinical Genetics, 2005, 67, 492-502.	1.0	105
139	Dilemma still not resolved. European Journal of Human Genetics, 2005, 13, 399-400.	1.4	1
140	Genetic professionals' reports of nondisclosure of genetic risk information within families. European Journal of Human Genetics, 2005, 13, 556-562.	1.4	117
141	Sequence changes in predicted promoter elements of STK11/LKB1 are unlikely to contribute to Peutz-Jeghers syndrome. BMC Genomics, 2005, 6, 38.	1.2	12
142	Men's Decision-Making About Predictive BRCA1/2 Testing: The Role of Family. Journal of Genetic Counseling, 2005, 14, 207-217.	0.9	67
143	Families and genetic testing: the case of Jane and Phyllis. , 2005, , 7-26.		2
144	Interpretation and dialogue in hermeneutic ethics. , 2005, , 57-76.		16

#	Article	IF	CITATIONS
145	Reading the genes., 2005,, 95-114.		O
146	A virtue-ethics approach., 2005,, 45-56.		5
147	Response to ethical dissections of the case. , 2005, , 213-224.		0
148	Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome. Journal of Medical Genetics, 2005, 43, e15-e15.	1.5	50
149	Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System. Journal of Clinical Oncology, 2005, 23, 5588-5596.	0.8	151
150	Family history of breast cancer. BMJ: British Medical Journal, 2005, 330, 26.	2.4	5
151	Deletions Involving Long-Range Conserved Nongenic Sequences Upstream and Downstream of FOXL2 as a Novel Disease-Causing Mechanism in Blepharophimosis Syndrome. American Journal of Human Genetics, 2005, 77, 205-218.	2.6	116
152	Family history of breast cancer. BMJ: British Medical Journal, 2005, 330, 730.2.	2.4	0
153	Role of next of kin in accessing health records of deceased relatives. BMJ: British Medical Journal, 2004, 328, 952-953.	2.4	9
154	Genetic information: a joint account?. BMJ: British Medical Journal, 2004, 329, 165-167.	2.4	120
155	Confidentiality and serious harm in genetics – preserving the confidentiality of one patient and preventing harm to relatives. European Journal of Human Genetics, 2004, 12, 93-97.	1.4	38
156	Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at $19q13.4$ and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. Genes Chromosomes and Cancer, 2004, 41, 163-169.	1.5	29
157	RNA analysis reveals splicing mutations and loss of expression defects inMLH1 andBRCA1. Human Mutation, 2004, 24, 272-272.	1.1	52
158	Improving the ascertainment of families at high risk of colorectal cancer: a prospective GP register study. British Journal of General Practice, 2004, 54, 267-71.	0.7	15
159	Concern for families and individuals in clinical genetics. Journal of Medical Ethics, 2003, 29, 70-73.	1.0	47
160	Further observations on LKB1/STK11 status and cancer risk in Peutz–Jeghers syndrome. British Journal of Cancer, 2003, 89, 308-313.	2.9	148
161	Education improves general practitioner (GP) management of familial breast/ovarian cancer: findings from a cluster randomised controlled trial. Journal of Medical Genetics, 2002, 39, 779-781.	1.5	18
162	Working towards ethical management of genetic testing. Lancet, The, 2002, 360, 1685-1688.	6.3	22

#	Article	IF	Citations
163	Revealing false paternity: some ethical considerations. Lancet, The, 2001, 357, 1033-1035.	6.3	88
164	Common hereditary cancers and implications for primary care. Lancet, The, 2001, 358, 56-63.	6.3	66
165	The Opinions, Expectations and Experiences of Women with a Family History of Breast Cancer Who Consult Their GP and Are Referred to Secondary Care. Public Health Genomics, 2001, 4, 239-243.	0.6	6
166	Evidence based case report: Advice about mammography for a young woman with a family history of breast cancer. BMJ: British Medical Journal, 2001, 322, 1040-1042.	2.4	19
167	Cystic fibrosis: A further case of an asymptomatic compound heterozygote. American Journal of Medical Genetics Part A, 2001, 103, 342-343.	2.4	4
168	What motivates interest in attending a familial cancer genetics clinic?. Familial Cancer, 2001, 2, 159-168.	0.9	29
169	A study of GP referrals to a family cancer clinic for breast/ovarian cancer. Family Practice, 2001, 18, 131-134.	0.8	48
170	Guidelines for referral to a regional genetics service: GPs respond by referring more appropriate cases. Family Practice, 2001, 18, 135-140.	0.8	59
171	Referral of patients with a family history of breast/ovarian cancer-GPs' knowledge and expectations. Family Practice, 2001, 18, 487-490.	0.8	51
172	Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. British Journal of General Practice, 2001, 51, 817-21.	0.7	52
173	A comparison of methods currently used in clinical practice to estimate familial breast cancer risks. Annals of Oncology, 2000, 11, 451-454.	0.6	16
174	Clinical geneticists' attitudes and practice towards testing for breast cancer susceptibility genes. Journal of Medical Genetics, 2000, 37, 157-160.	1.5	11
175	Hereditary cancer. Lancet Oncology, The, 2000, 1, 12-13.	5.1	1
176	Hereditary cancer – the evidence for current recommended management. Lancet Oncology, The, 2000, 1, 9-16.	5.1	18
177	Development and Evaluation of Educational Materials for Primary Care on Familial Breast and/or Ovarian Cancer. Disease Markers, 1999, 15, 156-156.	0.6	0
178	Ethical issues in genetics of mental disorders. Lancet, The, 1998, 352, 1004-1005.	6.3	17
179	Will gene testing cut risk of familial colorectal cancer?. Practitioner, 1998, 242, 306-10, 314.	0.3	0
180	The Insulin Gene Region and Susceptibility to Insulin-Dependent Diabetes Mellitus in Four Races; New Insights from Afro-Caribbean Race-Specific Haplotypes. Autoimmunity, 1997, 26, 11-22.	1.2	6

#	Article	IF	CITATIONS
181	Genetic Screening for Breast Cancer?. The Journal of the British Menopause Society, 1997, 3, 20-24.	1.3	О
182	Breast cancer: who is at risk?. Practitioner, 1997, 241, 757-9, 762.	0.3	0
183	Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genetics, 1995, 9, 284-292.	9.4	712
184	Reply to "Insulin expression: is VNTR allele 698 really anomalous?― Nature Genetics, 1995, 10, 379-380.	9.4	8
185	Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Human Molecular Genetics, 1995, 4, 501-506.	1.4	98
186	Multiple DNA variant association analysis: application to the insulin gene region in type I diabetes. American Journal of Human Genetics, 1994, 55, 1247-54.	2.6	38
187	Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nature Genetics, 1993, 4, 305-310.	9.4	253
188	Missense glucokinase mutation in maturity–onset diabetes of the young and mutation screening in late–onset diabetes. Nature Genetics, 1992, 2, 153-156.	9.4	141
189	Genomic variant sharing: a position statement. Wellcome Open Research, 0, 4, 22.	0.9	7
190	Mixed-methods evaluation of the NHS Genomic Medicine Service for paediatric rare diseases: study protocol. NIHR Open Research, 0, 1, 23.	0.0	1